CompletedNot Applicable

Endothelial Damage and Angiogenesis Biomarkers During COVID-19

Chile40 participantsStarted 2020-11-10

Plain-language summary

Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients older than 18 years
✓. Patient with a diagnosis of COVID-19 confirmed by PCR
✓. Patient with radiological image suggestive of COVID-19 with pending confirmation
✓. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula)
✓. Need for invasive mechanical ventilation.

Exclusion criteria

✕. Patient with an image suggestive of COVID-19 with negative PCR
✕. Anticoagulation users before admission for any reason.

What they're measuring

Change from Baseline Syndecan-1 concentration at 10th day

Timeframe: 24 Hours, 10 Days

Trial details

NCT IDNCT04609332

SponsorUniversity of Chile

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-09-26

View on ClinicalTrials.gov More Covid19 trials